Efficacy of docetaxel plus cisplatin versus taxol plus cisplatin for advanced non-small-cell lung cancer

Objective To assess its effectiveness and toxicity of domestic docetaxel plus cisplatin versus taxol plus cisplatin as first-line chemotherapy in patients with advanced non-small-cell lung cancer.Methods Sixty-five patients with stage Ⅲ or IV non-small-cell lung cancer(NSCLC) were randomized to receive either docetaxel plus cisplatin(Group DC) or taxol plus cisplatin(Group TC) every 3 weeks.Results Median survival was 9.6 and 9.0 months(P 0.05)for DC and TC arms,respectively.The corresponding 1-year survival rates were 32.3% and 30.8%(P 0.05),respectively,whereas the median time for progression of the disease was significantly longer in patients treated with DC(25 weeks in Group DC versus 20 weeks in Group TC(P 0.05).Overall response rate was39.3% and 28.2%(P 0.05)for DC and TC arms,respectively.Toxicity was as follows(DC:TC): myelosuppression,78.8%: 87.5%(P 0.05);vomiting,54.5%:59.4% (P 0.05);bone,arthrosis and muscle pain,9.1%:28.1%(P 0.05).Quality of life was improved in DC but not in TC patients.Conclusion Although docetaxel plus cisplatin versus taxol plus cisplatin as first-line chemotherapy in patients with advanced non-small-cell lung cancer produces equivalent overall survival,the DC regimen has a longer time for progression of the disease,and nerve and muscles toxicity is lower.These findings demonstrate that docetaxel plus cisplatin combination is a favorable therapeutic option for first-line treatment of advanced NSCLC.